GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revance Therapeutics Inc (STU:RTI) » Definitions » Notes Receivable

Revance Therapeutics (STU:RTI) Notes Receivable : €0.0 Mil (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Revance Therapeutics Notes Receivable?

Revance Therapeutics's Notes Receivable for the quarter that ended in Mar. 2024 was €0.0 Mil.


Revance Therapeutics Notes Receivable Historical Data

The historical data trend for Revance Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revance Therapeutics Notes Receivable Chart

Revance Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Revance Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Revance Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Revance Therapeutics Notes Receivable Related Terms

Thank you for viewing the detailed overview of Revance Therapeutics's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Revance Therapeutics (STU:RTI) Business Description

Traded in Other Exchanges
Address
1222 Demonbreun Street, Suite 2000, Nashville, TN, USA, 37203
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Revance Therapeutics (STU:RTI) Headlines

No Headlines